Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of 5-Methoxytryptamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.78 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.78 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.62 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.61 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.78 |
| ▸ | HTR1B | P28222 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.78 |
| ▸ | HTR7 | P34969 | 3/20 | 0.78 |
| ▸ | HTR6 | P50406 | 2/20 | 0.78 |
| ▸ | HTR1D | P28221 | 2/20 | 0.78 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Methoxytryptamine SCHEMBL30933118 | 1.00 | HTR1A (0.78) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL31240192 | 1.00 | HTR1A (0.78) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL7094589 | 1.00 | HTR1A (0.78) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL30960099 | 0.99 | HTR1A (0.76) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL30812526 | 0.91 | HTR1A (0.84) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL27094903 | 0.91 | HTR1A (0.84) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL41982 | 0.88 | HTR1A (1.00) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL29390103 | 0.88 | HTR1A (1.00) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL6830006 | 0.88 | CYP1A2 (0.78) | HTR1AHTR1BCYP1A2HTR7HTR2C | |
| 5-Methoxytryptamine SCHEMBL31109114 | 0.87 | NPSR1 (1.00) | HTR1AHTR1BCYP1A2HTR7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024229352-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024229352-A3 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024229352-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229352-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20030114512-A1 | Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma | ALCON UNIVERSAL LTD. (CH) | 2003-06-19 | — | — | US | disclosed |
| EP-1263434-A1 | COMPOUNDS WITH 5-HT 2 AND 5-HT 1A AGONIST ACTIVITY FOR TREATING GLAUCOMA | Alcon, Inc (CH) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001070223-A1 | COMPOUNDS WITH 5-HT2 AND 5-HT1A AGONIST ACTIVITY FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114512-A1 | Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma | HTR1A, HTR2A, HTR5A | HTR2C 6/4885HTR2A 2/4885SLC6A2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.